Adicet Bio, Inc. (ACET)
NASDAQ: ACET · Real-Time Price · USD
0.967
-0.063 (-6.11%)
At close: Nov 20, 2024, 4:00 PM
0.988
+0.021 (2.15%)
Pre-market: Nov 21, 2024, 5:06 AM EST
Adicet Bio Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
143
Market Cap
79.69M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Assertio Holdings | 125.76M |
908 Devices | 55.16M |
LENSAR | 48.87M |
CASI Pharmaceuticals | 22.06M |
CervoMed | 10.07M |
Ikena Oncology | 659.00K |
ACET News
- 2 days ago - Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma - Business Wire
- 3 days ago - Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases - Business Wire
- 5 days ago - Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024 - Business Wire
- 14 days ago - Adicet Reports Third Quarter 2024 Financial Results and Provides Business Updates - Business Wire
- 16 days ago - Adicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024 - Business Wire
- 20 days ago - Adicet Bio to Participate in Upcoming Investor Conferences - Business Wire
- 20 days ago - Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 5 weeks ago - Adicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome - Business Wire